BioSpace News Archive

Waters Corporation announced that Udit Batra Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 8, 2024 at 7:30PM Eastern Time.

Vor Bio announced that, effective as of December 20, 2023, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 2,500 shares of Vor Bio’s common stock and restricted stock units representing the right to receive an aggregate of 3,750 shares of Vor Bio’s common stock to one newly hired employee.

10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 9:00 a.m. Pacific Time.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 42nd Annual JPMorgan Healthcare Conference taking place January 8 – January 12, 2024.

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced today that the Company has amended the previously announced 2020 option and license agreement with AbbVie for acazicolcept.

Danaher Corporation announced that it will webcast its quarterly earnings conference call for the fourth quarter 2023 on Tuesday, January 30, 2024 beginning at 8:00 a.m. ET and lasting approximately one hour.

Geron Corporation, a late-stage clinical biopharmaceutical company, reported that it has granted non-statutory stock options to purchase an aggregate of 417,490 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

Justera Health Ltd. (CSE: VTAL) (OTC Pink: SCRSF) (“Justera” or the “Company”) is pleased to announce that subsequent to the news release dated November 2, 2023, the Company’s wholly-owned subsidiary

Theravance Biopharma, Inc. (“Theravance” or the “Company”) (NASDAQ: TBPH) today announced the appointment to its Board of Directors of Jeremy Grant, who serves as a Special Advisor to Irenic Capital Management LP (“Irenic”).

AstraZeneca and Ionis’ WAINUA™ (eplontersen) has been approved in the US for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, commonly referred to as hATTR-PN or ATTRv-PN.